Research
Molecular
Long-acting GLP-1 pharmacological agents have been approved for the treatment of obesity.
Practitioners can consider long-acting GLP-1 agents as viable options for obesity management.
StrongSupportsmedium confidence
Molecular modifications of GLP‐1...led to the development of long‐acting subcutaneous or oral pharmacological agents that have been approved for the treatment of obesity.
Why this rating
The abstract summarizes findings from a review, indicating a comprehensive analysis.
Source
Incretin impact on gastric function in obesity: physiology, and pharmacological, surgical and endoscopic treatments
Michael Camilleri · The Journal of Physiology · 2024
DOI 10.1113/jp287535
reviewCited 6×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Molecular
- QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.Strong
- Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.Strong
- The Low-Fat Plus diet resulted in a greater reduction in total cholesterol compared to the Low-Fat diet, with changes of -0.46 mmol/L (-17.6 mg/dL) versus -0.24 mmol/L (-9.2 mg/dL) respectively (P = 0.01).Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →